Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
AIDS (London, England)
|
May 12, 2000
Absence of virological changes after acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1-RNA levels
B E Sha, V A Johnson, M A Kendall, et al.
Journal of Viral Hepatitis
|
March 9, 2017
Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus-infected persons
K W Chew, D Bhattacharya, T B Horwich, et al.
AIDS (London, England)
|
July 9, 1999
The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group
R H Haubrich, S J Little, J S Currier, et al.
The Journal of Infectious Diseases
|
April 27, 2000
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
J J Eron, L M Smeaton, S A Fiscus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 31, 2001
A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy
R H Haubrich, J S Currier, D N Forthal, et al.
AIDS (London, England)
|
August 16, 2001
A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l
S L Koletar, A E Heald, D Finkelstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 14, 2000
Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group
M P Dubé, D Sprecher, W K Henry, et al.
The Journal of Infectious Diseases
|
February 22, 2001
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373
R M Gulick, L M Smeaton, R T D'Aquila, et al.
The Journal of Infectious Diseases
|
March 9, 1999
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team
R L Murphy, R M Gulick, V DeGruttola, et al.
Clinical and Diagnostic Laboratory Immunology
|
November 1, 2001
Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M. avium infection
C F von Reyn, P L Williams, H M Lederman, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
AIDS (London, England)
|
May 12, 2000
Absence of virological changes after acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1-RNA levels
B E Sha, V A Johnson, M A Kendall, et al.
Journal of Viral Hepatitis
|
March 9, 2017
Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus-infected persons
K W Chew, D Bhattacharya, T B Horwich, et al.
AIDS (London, England)
|
July 9, 1999
The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group
R H Haubrich, S J Little, J S Currier, et al.
The Journal of Infectious Diseases
|
April 27, 2000
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
J J Eron, L M Smeaton, S A Fiscus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 31, 2001
A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy
R H Haubrich, J S Currier, D N Forthal, et al.
AIDS (London, England)
|
August 16, 2001
A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l
S L Koletar, A E Heald, D Finkelstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 14, 2000
Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group
M P Dubé, D Sprecher, W K Henry, et al.
The Journal of Infectious Diseases
|
February 22, 2001
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373
R M Gulick, L M Smeaton, R T D'Aquila, et al.
The Journal of Infectious Diseases
|
March 9, 1999
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team
R L Murphy, R M Gulick, V DeGruttola, et al.
Clinical and Diagnostic Laboratory Immunology
|
November 1, 2001
Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M. avium infection
C F von Reyn, P L Williams, H M Lederman, et al.
Page
of 4